Partners

At Nanoligent, we are proud to collaborate with a distinguished network of partners committed to advancing cancer treatment. Our main investors provide invaluable support and resources, fueling our pioneering work in nanobiotechnology, while Institutional partners play a crucial role in our research and development efforts, offering expertise and facilities that are essential for our success.

Together, we are forging a path towards groundbreaking therapeutic solutions.

Financial Investors

Nanoligent is backed by esteemed investors Avanteca, Italian Angels for Growth, and I&I Bio, whose financial and strategic support propels our cutting-edge research in nanobiotechnology and cancer treatment.
Logo of Avanteca, a leading investor in cutting-edge biotechnology ventures, supporting innovative cancer treatment solutions
Logo of Italian Angels for Growth, a network of investors championing the progress of pioneering startups in healthcare and nanobiotechnology
Logo of I&I BIO, a key financial and strategic partner dedicated to fostering advancements in biotechnological research and development

Institutional Partners

Our work is further enriched through partnerships with leading institutions. These collaborations provide essential research infrastructure and academic expertise, vital for innovation.

IBB-UAB-Institut de Biotecnologia i de Biomedicina

Institut de Biotecnologia i de Biomedicina UAB

Logo-Institut Sant Pau-Nanoligent-Institutional-Partners

Institut d’Investigacions Biomèdiques Sant Pau

CIBER-BBN

CIBER-BBN
Bellaterra

Logo-UAB-Nanoligent-Institutional-Partner

Universitat Autònoma de Barcelona

Logo-NCI-Nanoligent-Institutional-Partners

Nanotechnology Characterization Laboratory

Logo-Ciemat-Nanoligent-Institutional-Partners

Ciemat

Public Funding

Proyecto “New protein-based nanodrugs for the development of targeted tumor-agnostic therapy” con expediente CPP2021-008946 financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR 

Proyecto “New generation of CXCR4-targeted theranostic combination: Development of radiolabeled nanoparticles against CXCR4-positive cancer cells” con expediente CPP2022-009751 financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR